Fibrocell Science (FCSC) Inactive 10-Q2019 Q1 Quarterly report

Filed: 15 May 19, 4:18pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: alternative, benchmark, BLA, borrow, borrowing, Boulevard, breakdown, budget, building, cancellable, Castle, CCP, CMC, collateralized, conflict, Creek, currency, degenerative, diagnosed, disagree, Eagleview, effort, endpoint, entailed, expedient, feel, feet, forty, hindsight, human, illustrated, illustrative, impairment, implicit, incremental, infancy, insolvency, launch, lessee, lessor, lowest, met, methodology, November, optimally, oversee, Pennsylvania, people, prioritize, Priority, profit, pursue, readily, recovery, regimen, renewal, resource, revised, sensitivity, successful, timeframe, uncured, undertaken, unexpected, unsecured, upfront, USD, valid, viable, Voucher

Removed: activated, adequate, administered, advanced, advisor, anchoring, announcement, approach, assessed, assist, attention, attract, attributable, audit, autoimmune, bandaging, baseline, begin, billion, biodistribution, biologic, bleomycin, blistering, body, breaking, Breakthrough, broad, Bulletin, butterfly, called, Canaccord, children, cleanroom, collaborate, collected, combination, commit, commonly, comparing, complexity, comprehensive, conducted, conducting, consuming, content, continuing, contracted, cryogenic, death, debilitating, decision, deferral, demonstrated, depth, dermal, detected, devastatingly, difficulty, disability, discomfort, discounted, discovering, disposition, disruptive, distinctive, divert, DSMB, enacted, enactment, encoded, established, evaluate, exceeding, excessive, excluding, existence, explore, exploring, expose, expression, extensive, facilitate, feeding, firm, fluctuate, foot, found, fragile, friction, function, Genuity, good, group, halt, histology, hold, hydrogel, immunocompromised, immunodeficiency, immunofluorescence, improve, incorporate, indefinite, independent, inherit, intact, integrative, intradermal, investigational, investment, layer, legislation, light, low, mandatorily, manufacturer, maximize, maximizing, Medicine, merger, mice, microscopy, monitored, motivate, movement, mRNA, muscle, mutation, navigating, negatively, noncancelable, noncontrolling, nonpublic, observed, orally, organ, owed, pain, painful, paired, paragraph, pathology, pattern, pending, persistence, petition, pharmacology, physical, practice, presence, Prevention, provisional, quality, recognition, redeemable, referred, regain, Regenerative, reimburse, Replacement, requiring, resignation, response, rest, RheoSwitch, round, RTS, rubbing, SAB, scarring, SCID, scratching, Secondary, section, sequelae, session, show, showed, source, speculation, staggered, stockholder, stop, storage, strike, submission, submitting, subtype, switch, System, targeting, TCJA, test, testing, Therapeutic, timetable, timing, topical, toxicology, translating, turnover, ultrasound, unmet, untreated, UVA, Veledimex, warehousing, weight

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

FCSC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019 of Fibrocell Science, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John M. Maslowski, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

•The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and

•The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:	May 15, 2019
By:	/s/ John M. Maslowski
	John M. Maslowski
	President and Chief Executive Officer
	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to Fibrocell Science, Inc. and will be retained by Fibrocell Science, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.